Pfizer: priority review in cervical cancer
Tivdak is an antibody-conjugate for patients with recurrent or metastatic cervical cancer with disease progression during or after first-line chemotherapy.
The 'priority review' designation means that the FDA aims to rule on the application within six months, compared with ten months for a standard review.
In this case, the agency's final decision is expected in May.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction